Universal reference book for medicines
Product name: PIAKLEDIN 300 (PIASCLEDINE 300)

Active substance: non-appropriated, Soya-bean oil

Type: A drug regulating the metabolism in cartilaginous tissue

Manufacturer: Laboratoires EXPANSCIENCE (France)
Composition, form of production and packaging
?
Capsules (type I) with a white cap and an opaque white body, marked "P 300"; contents of capsules - brown paste.
1 caps.

unsaponifiable compounds of avocado oil 100 mg

unsaponifiable soybean oil compounds 200 mg

Excipients: butylhydroxytoluene - 30 mcg, silicon colloidal dioxide - 7 mg.

The composition of the capsule body: titanium dioxide - 2%, gelatin - up to 100%.

Composition of capsule capsule: titanium dioxide - 2%, gelatin - up to 100%.

The composition of the binder solution (to seal the capsule): polysorbate 80 - 250 Ојg, gelatin - 5.75 mg.

The composition of the ink "TekPrint в„ў SW-9008 Black Ink" (for labeling the capsule): shellac, ethanol, isopropanol, butanol, propylene glycol, ammonia solution concentrated, potassium hydroxide, iron oxide black.

15 pcs.
- blisters (2) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2016.

PHARMACHOLOGIC EFFECT

A preparation of vegetable origin regulating the processes of metabolism in cartilaginous tissue.

Has a symptomatic anti-inflammatory and analgesic effect on the joints.

It helps to slow the development of the degenerative process in the cartilaginous tissue of the joints, reduces joint pain associated with this process, restores the motor function of the patient.

In the conducted experimental studies, it was proved that the drug has a regenerating effect on the cartilage, stimulating the synthesis of collagen in articular chondrocytes.
Unsaponifiable soybean oil compounds and avocado oils increase the production of collagen and inhibit the stimulating effect of interleukin-1 (IL-1) on the synthesis of collagenase.
Unsaponifiable soybean oil compounds and avocado oils:

- increase the production of an inhibitor of plasminogenesis activator, thereby reducing cartilage damage, either indirectly through the stimulation of metalloproteinases, or by direct action on the cartilage, activating the degradation of proteoglycans, which prevents the destruction of cartilage;

- increase the effect of the transforming growth factor?
1 (TGF) in chondrocytes, which has a powerful anabolic property;
- regulate the synthesis of macromolecules of the intercellular substance of the articular cartilage, are a powerful stimulator of the synthesis of the macromolecule of hyaline cartilage, as well as periodontal tissue, preventing the loss of teeth.

PHARMACOKINETICS

Data on the pharmacokinetics of Piascladin 300 are not available.

INDICATIONS

- complex therapy of osteoarthrosis of knee and hip joints of stages I-III;

- adjuvant therapy of periodontitis.

DOSING MODE

The drug is taken orally 1 caps / day, preferably in the morning during a meal, with 250 ml of water.
The course of treatment is 6 months.
An increase in the duration and holding of repeated courses of treatment is possible after consultation with the doctor.

SIDE EFFECT

Possible: allergic reactions.

Very rarely: increased activity of hepatic transaminases, alkaline phosphatase, GGT, and bilirubin levels.

CONTRAINDICATIONS

- age up to 18 years;

- Pregnancy;

- lactation period (breastfeeding);

- Hypersensitivity to the components of the drug.

PREGNANCY AND LACTATION

The drug is not recommended for use in pregnancy and lactation (breastfeeding).

APPLICATION FOR CHILDREN

Contraindicated in the use of drugs under the age of 18 years.

SPECIAL INSTRUCTIONS

At the initial stage of treatment, the use of Piascladin 300 can be combined with the intake of NSAIDs and / or analgesics.

Impact on the ability to drive vehicles and manage mechanisms

Does not affect the activity requiring increased concentration of attention and speed of psychomotor reactions.

OVERDOSE

Until now, no cases of an overdose of Piaskcleidine 300 have been reported.

DRUG INTERACTION

Interaction with other drugs is not described.

TERMS OF RELEASE FROM PHARMACY

The drug is approved for use as a means of OTC.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a place protected from light, inaccessible to children at a temperature of 15 В° to 25 В° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!